Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial

Aim: Evaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women. Methods: Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end p...

Descripción completa

Detalles Bibliográficos
Autores principales: Clayton, Anita H, Althof, Stanley E, Kingsberg, Sheryl, DeRogatis, Leonard R, Kroll, Robin, Goldstein, Irwin, Kaminetsky, Jed, Spana, Carl, Lucas, Johna, Jordan, Robert, Portman, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384512/
https://www.ncbi.nlm.nih.gov/pubmed/27181790
http://dx.doi.org/10.2217/whe-2016-0018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384512/
https://www.ncbi.nlm.nih.gov/pubmed/27181790
http://dx.doi.org/10.2217/whe-2016-0018

Ejemplares similares